合成生物学的医学应用研究进展
Progress of Synthetic Biology Research in Medical Applications
Progress of Synthetic Biology Research in Medical Applications
作者
崔金明(中国科学院深圳先进技术研究院 深圳 518055)
王力为(中国科学院 前沿科学与教育局 北京 100864)
常志广(中国科学院深圳先进技术研究院 深圳 518055)
臧中盛(中国科学院深圳先进技术研究院 深圳 518055)
刘陈立(中国科学院深圳先进技术研究院 深圳 518055)
王力为(中国科学院 前沿科学与教育局 北京 100864)
常志广(中国科学院深圳先进技术研究院 深圳 518055)
臧中盛(中国科学院深圳先进技术研究院 深圳 518055)
刘陈立(中国科学院深圳先进技术研究院 深圳 518055)
中文关键词
人工细胞;人工细菌;人工病毒;人工噬菌体
英文关键词
synthetic cell;synthetic bacteria;synthetic virus;synthetic phage
中文摘要
在医学应用领域，合成生物学以人工设计的基因线路改造人体自身细胞，或改造细菌、病毒等人工生命体，再使其间接作用于人体。这些经人工设计的生命体能够感知疾病特异信号或人工信号、特异性靶向异常细胞和病灶区域、表达报告分子或释放治疗药物，从而实现对人体生理状态的监测，以及对肿瘤、代谢疾病、耐药菌感染等典型疾病的诊断与治疗。文章将综述了合成生物学的医学应用领域近期的一些研究进展。
英文摘要
In the field of medical applications, synthetic biology researchers design genetic circuits to modify human cells, or to modify synthetic organisms such as bacteria and viruses and make them interact with the human body. These artificially designed organisms are capable of perceiving disease-specific signals or artificial signals, targeting abnormal cells and foci, expressing reporter molecules or releasing therapeutic drugs, thus enabling the monitoring of human physiological conditions and the diagnosis and treatment of typical diseases such as tumors, metabolic diseases, and drug-resistant bacteria infections. This article will comprehensively describe some recent research progress.
DOI10.16418/j.issn.1000-3045.2018.11.010
作者简介
崔金明 中国科学院深圳先进技术研究院副研究员,中国科学院青年创新促进会会员。美国普渡大学获生物化学博士学位,美国约翰·霍普金斯大学医学院从事博士后研究。研究领域为膜蛋白元件的定向进化、应用微生物学,以及合成生物学科发展政策与伦理研究。作为项目负责人,主持国家级基金2项,地方基金4项。
E-mail:jm.cui@giat.ac.cn
CUI Jinming Associate Investigator at the Shenzhen Institutes of Advanced Technology,Chinese Academy of Sciences (CAS),and member of the Youth Innovation Promotion Association,CAS.He received his Ph.D.in biochemistry from Purdue University,followed by postdoctoral research at School of Medicine,Johns Hopkins University.His current research interests include directed evolution of membrane proteins,applied microbiology,and policy and ethics study of synthetic biology.As a project leader,he has presided over two national funds and four regional funds.
E-mail:jm.cui@giat.ac.cn
刘陈立 中国科学院深圳先进技术研究院合成生物学研究所所长、研究员,定量合成生物学中心主任。主要研究方向为合成生物基因线路探索生物学的基本原理、肿瘤治疗和定向进化方法开发。牵头筹建"深圳合成生物研究重大科技基础设施"。入选中组部"青年千人计划"、中国科学院"百人计划"。荣获2012年度"香港青年科学家奖"和"李嘉诚奖"、2017年度中源协和生命医学奖创新突破奖。担任ACS Synthetic Biology编委、中国生物工程学会合成生物学专业委员会副主任兼秘书长、深圳合成生物学协会会长等。
E-mail:cl.liu@siat.ac.cn
LIU Chenli Principal Investigator and Director of the Institute of Synthetic Biology,Shenzhen Institutes of Advanced Technology,CAS,and Director of the Center for Quantitative Synthetic Biology.His research interests include exploring the fundamental principles of biology with synthetic gene circuits,tumor therapy,and development of directed evolution methods.He also leads the preparation of the "Shenzhen Major Science and Technology Infrastructure for Synthetic Biology Research" as the Chief Scientist.He is an awardee of the national "Thousand Youth Talents Program" and the "Hundred Talents Program" of CAS.He has been awarded the "Hong Kong Young Scientist Award" and "Li Ka-shing Award" in 2012,and the Zhongyuan Concord Biomedicine Innovation Breakthrough Award in 2017.He serves as an editor of ACS Synthetic Biology,as the Deputy Director and Secretary-General of the Chinese Bioengineering Society,and as President of the Shenzhen Synthetic Biology Association.
E-mail:cl.liu@siat.ac.c
E-mail:jm.cui@giat.ac.cn
CUI Jinming Associate Investigator at the Shenzhen Institutes of Advanced Technology,Chinese Academy of Sciences (CAS),and member of the Youth Innovation Promotion Association,CAS.He received his Ph.D.in biochemistry from Purdue University,followed by postdoctoral research at School of Medicine,Johns Hopkins University.His current research interests include directed evolution of membrane proteins,applied microbiology,and policy and ethics study of synthetic biology.As a project leader,he has presided over two national funds and four regional funds.
E-mail:jm.cui@giat.ac.cn
刘陈立 中国科学院深圳先进技术研究院合成生物学研究所所长、研究员,定量合成生物学中心主任。主要研究方向为合成生物基因线路探索生物学的基本原理、肿瘤治疗和定向进化方法开发。牵头筹建"深圳合成生物研究重大科技基础设施"。入选中组部"青年千人计划"、中国科学院"百人计划"。荣获2012年度"香港青年科学家奖"和"李嘉诚奖"、2017年度中源协和生命医学奖创新突破奖。担任ACS Synthetic Biology编委、中国生物工程学会合成生物学专业委员会副主任兼秘书长、深圳合成生物学协会会长等。
E-mail:cl.liu@siat.ac.cn
LIU Chenli Principal Investigator and Director of the Institute of Synthetic Biology,Shenzhen Institutes of Advanced Technology,CAS,and Director of the Center for Quantitative Synthetic Biology.His research interests include exploring the fundamental principles of biology with synthetic gene circuits,tumor therapy,and development of directed evolution methods.He also leads the preparation of the "Shenzhen Major Science and Technology Infrastructure for Synthetic Biology Research" as the Chief Scientist.He is an awardee of the national "Thousand Youth Talents Program" and the "Hundred Talents Program" of CAS.He has been awarded the "Hong Kong Young Scientist Award" and "Li Ka-shing Award" in 2012,and the Zhongyuan Concord Biomedicine Innovation Breakthrough Award in 2017.He serves as an editor of ACS Synthetic Biology,as the Deputy Director and Secretary-General of the Chinese Bioengineering Society,and as President of the Shenzhen Synthetic Biology Association.
E-mail:cl.liu@siat.ac.c
